Gavi and Bavarian Nordic Team Up for Mpox Vaccine Supply
The advance purchase agreement (APA) marks a crucial move towards ensuring that African nations have quick access to essential vaccines in light of emerging health threats. Funded by Gavi’s First Response Fund, this initiative emphasizes the need for readiness in tackling future health emergencies, especially after the COVID-19 pandemic exposed weaknesses in global health systems.
Vaccine Doses Secured for 2024
Under this agreement, Gavi has successfully arranged for the delivery of 500,000 doses of the MVA-BN Mpox vaccine in 2024. This well-thought-out supply plan is designed to effectively address and reduce outbreaks, particularly in areas severely impacted by the virus.
Agreement Details
Bavarian Nordic A/S and Gavi jointly announced the importance of this collaboration, highlighting how the First Response Fund enhances their ability to respond quickly, facilitating essential vaccine access during emergencies.
First Response Fund: A Quick Action Framework
Established with Gavi's partners, the First Response Fund aims to speed up early funding for crises that arise unexpectedly, like the recent Mpox outbreak. Dr. Sania Nishtar, Gavi's CEO, stressed their commitment to working closely with countries in need, ensuring that vaccines are delivered effectively to communities that require them most.
A Focused Commitment to Global Health
This agreement illustrates Bavarian Nordic's long-standing dedication to providing life-saving vaccines in partnership with global health organizations. Paul Chaplin, the company's President & CEO, expressed pride in their efforts to increase vaccine availability for vulnerable populations, particularly in developing areas.
Strengthening Health Security in Africa
Gavi's proactive strategy not only aims to provide vaccines quickly but also focuses on training healthcare professionals and engaging communities to ensure vaccination campaigns are effective and widespread.
Creating a Sustainable Vaccine System
In addition to immediate responses, Gavi plans to develop a stockpile of vaccines and establish sustainable manufacturing capabilities within Africa. This comprehensive strategy is viewed as essential for safeguarding public health against both existing and future outbreaks.
About the MVA-BN Vaccine
The MVA-BN vaccine, known as Modified Vaccinia Ankara-Bavarian Nordic, is notable for being the only non-replicating mpox vaccine approved in major markets such as the U.S., Canada, and Europe. Initially created as a smallpox vaccine with U.S. government collaboration, it plays a vital role in vaccination efforts for the general population.
Ongoing Research and Development
Bavarian Nordic is actively working on expanding the vaccine's use to various age groups, including adolescents and children. The company is dedicated to ensuring that the vaccine remains a strong option for public health initiatives around the globe.
About Bavarian Nordic
Globally recognized as a leading vaccine manufacturer, Bavarian Nordic is committed to public health. Their contributions in providing vaccines against smallpox and mpox exemplify many years of partnership and innovation with governments and health organizations worldwide.
About Gavi, the Vaccine Alliance
Gavi plays an essential role in global public health, working to ensure that vaccines reach children in developing countries while also striving to reduce child mortality rates. Since its inception, Gavi has positively impacted over a billion children, enhancing global health security through collaborative efforts.
Frequently Asked Questions
What is the purpose of the advance purchase agreement?
The APA secures 500,000 doses of mpox vaccines for African nations, promoting a quick response to possible outbreaks.
How is Gavi funding the vaccine procurement?
This procurement is funded through Gavi’s First Response Fund, which was created to handle urgent health emergencies effectively.
What is the timeline for the vaccine delivery?
The vaccines are set to be delivered in 2024, ensuring timely availability for affected countries.
How does Bavarian Nordic contribute to public health?
Bavarian Nordic provides essential vaccines and shows a commitment to improving health security for vulnerable populations globally.
What are Gavi’s plans after this agreement?
Gavi aims to build a stockpile of vaccines and establish sustainable manufacturing capabilities in Africa, preparing for future health challenges.
